Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Klaus Buehner"'
Autor:
Frank-Thorsten Hafner, Carsten Schmeck, Roland Heinig, Alexandros Vakalopoulos, Hilmar Bischoff, Klemens Lustig, Klaus Buehner, Stefan Willmann, Volkhart Min-Jian Li, Olaf Weber
Publikováno v:
British Journal of Clinical Pharmacology. 73:219-231
The purpose of this work was to support the prediction of a potentially effective dose for the CETP-inhibitor, BAY 60-5521, in humans.A combination of allometric scaling of the pharmacokinetics of the CETP-inhibitor BAY 60-5521 with pharmacodynamic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bef16ac0e693cddb037a092a49ba25
https://doi.org/10.1111/j.1365-2125.2011.04064.x
https://doi.org/10.1111/j.1365-2125.2011.04064.x
Autor:
Dietrich Seidel, Bernhard Beckermann, Dieter Zimmerd, Wolfram Steinke, Frank Mauler, Corinna Weinz, Klaus Buehner, Joachim Schuhmacher, Thomas Schwarz
Publikováno v:
Biopharmaceutics & Drug Disposition. 26:259-268
Repinotan hydrochloride (repinotan) is a highly potent and selective 5-HT1A full receptor agonist. The ability of repinotan to cross the blood–brain barrier (BBB) and penetrate into rat brain tissue was investigated, because rapid penetration into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59da9526dc43fd6da5ed96220761e2b0
https://doi.org/10.1002/bdd.458
https://doi.org/10.1002/bdd.458
Autor:
Dietrich Seidel, Andreas Baumann, Wolfram Steinke, Thomas Schwarz, Frank Hucke, Klaus Buehner
Publikováno v:
Blood. 124:1473-1473
Introduction: Although there is no evidence for PEG-related safety issues with PEGylated proteins in the clinic, questions relating to the pharmacokinetics including disposition and excretion of PEG are being raised more frequently by health authorit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e41b59e4aa67098d9477acf1190c09c
https://doi.org/10.1182/blood.v124.21.1473.1473
https://doi.org/10.1182/blood.v124.21.1473.1473